Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$4.81 -2.0%	$5.62	$4.71 ▼ $12.43	$695.62M	1.36	2.22 million shs	2.10 million shs
CYDY CytoDyn	$0.15	$0.17	$0.13 ▼ $0.42	$149.77M	0.16	2.77 million shs	806,934 shs
EIDX Eidos Therapeutics	$122.21	$123.21	$28.39 ▼ $132.54	$4.75B	-0.16	128,113 shs	N/A
MYOV Myovant Sciences	$26.98	$26.96	$7.67 ▼ $27.06	$2.62B	2.17	1.17 million shs	2.26 million shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-1.80%	-1.60%	-3.54%	-37.69%	-55.36%
CYDY CytoDyn	0.00%	-6.62%	-11.38%	-17.55%	-51.71%
EIDX Eidos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MYOV Myovant Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	0.8258 of 5 stars	3.4	1.0	0.0	0.0	1.8	0.0	0.6
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYOV Myovant Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.75	Moderate Buy	$10.00	107.90% Upside
CYDY CytoDyn	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A
MYOV Myovant Sciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AUPH, MYOV, CYDY, and EIDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/1/2024	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
2/23/2024	AUPH Aurinia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
2/22/2024	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $13.00
2/16/2024	AUPH Aurinia Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$9.50 ➝ $9.00
2/16/2024	AUPH Aurinia Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$13.00 ➝ $8.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$175.51M	3.96	N/A	N/A	$2.63 per share	1.83
CYDY CytoDyn	$270K	554.72	N/A	N/A	($0.12) per share	-1.26
EIDX Eidos Therapeutics	$26.69M	177.99	N/A	N/A	$4.57 per share	26.74
MYOV Myovant Sciences	$230.97M	11.36	N/A	N/A	($5.04) per share	-5.35

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	-$78.02M	-$0.54	N/A	8.75	N/A	-44.45%	-20.10%	-14.84%	5/2/2024 (Confirmed)
CYDY CytoDyn	-$79.82M	-$0.05	N/A	∞	N/A	N/A	N/A	-478.47%	N/A
EIDX Eidos Therapeutics	-$37.83M	-$1.03	N/A	N/A	N/A	N/A	-65.21%	-53.04%	N/A
MYOV Myovant Sciences	-$205.98M	-$1.91	N/A	N/A	N/A	-48.47%	N/A	-39.36%	N/A

Latest AUPH, MYOV, CYDY, and EIDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/2/2024	N/A	AUPH Aurinia Pharmaceuticals	-$0.17	N/A	+$0.17	N/A	N/A	N/A
4/15/2024	Q3 2024	CYDY CytoDyn	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
2/15/2024	12/31/2023	AUPH Aurinia Pharmaceuticals	-$0.16	-$0.19	-$0.03	-$0.19	$45.00 million	$45.10 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A	N/A
MYOV Myovant Sciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.20	5.50	4.99
CYDY CytoDyn	N/A	0.08	0.07
EIDX Eidos Therapeutics	0.14	11.10	11.10
MYOV Myovant Sciences	N/A	1.57	1.45

Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CYDY CytoDyn	5.06%
EIDX Eidos Therapeutics	31.40%
MYOV Myovant Sciences	30.62%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	4.30%
CYDY CytoDyn	0.71%
EIDX Eidos Therapeutics	70.10%
MYOV Myovant Sciences	1.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	144.62 million	138.40 million	Optionable
CYDY CytoDyn	12	992.87 million	985.82 million	Not Optionable
EIDX Eidos Therapeutics	70	38.87 million	N/A	Not Optionable
MYOV Myovant Sciences	407	97.24 million	95.39 million	Not Optionable

AUPH, MYOV, CYDY, and EIDX Headlines

Source	Headline
	World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs uk.finance.yahoo.com - April 18 at 9:20 AM
	Researchers discover urine-based test to detect head and neck cancer eurekalert.org - April 16 at 2:43 PM
	Social Sciences & Interdisciplinary Studies csus.edu - April 4 at 11:01 PM
	Roivant reveals positive immune drug data, share buyback plans biopharmadive.com - April 2 at 3:38 PM
	Computer Science on Campus bc.edu - March 15 at 9:42 AM
	Exposure to Teratogenic Medicine Common Before Prenatal Care medpagetoday.com - February 6 at 9:50 AM
	2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout Year forbes.com - January 15 at 2:17 PM
	Global $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Region finance.yahoo.com - January 11 at 8:54 PM
	ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives finance.yahoo.com - January 3 at 9:54 AM
	Vivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ... dailymail.co.uk - December 28 at 3:21 PM
	Sumitomo Pharma CEO Myrtle Potter Focuses On Leading By Example healthleadersmedia.com - December 22 at 9:52 AM
	Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight finance.yahoo.com - December 8 at 9:34 AM
	Despite Effective Therapies, Fibroid Care Still Lacking medscape.com - November 27 at 4:27 PM
	NCCN Announces Funding for Advanced Prostate Cancer Research Projects markets.businessinsider.com - November 21 at 9:43 AM
	BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in ... br.advfn.com - November 14 at 7:11 PM
	News - Orgovyx thepharmaletter.com - October 24 at 3:11 PM
	News - Myovant Sciences thepharmaletter.com - October 24 at 3:11 PM
	Myovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings barrons.com - October 22 at 10:14 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant ... bakersfield.com - October 3 at 7:01 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV benzinga.com - September 26 at 8:57 PM
	Sumitomo Sued Over Skadden’s Alleged Conflicts in Myovant Merger news.bloomberglaw.com - September 14 at 3:31 PM
	4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chief marketwatch.com - September 12 at 6:07 PM
	Hormone Sensitive Advanced Prostate Cancer Treatment Market Set to Soar at 7.2% CAGR, Exceeding US$ 24.94 Billion by 2033 \| Says FMI fmiblog.com - September 8 at 6:10 PM
	Vivek Ramaswamy claims he is too busy campaigning to give evidence msn.com - August 29 at 1:24 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aurinia Pharmaceuticals

NASDAQ:AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

CytoDyn

OTCMKTS:CYDY

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Eidos Therapeutics

NASDAQ:EIDX

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Myovant Sciences

NYSE:MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial